Medovir (Aciclovir)

Aciclovir is a nucleoside analogue that is phosphorylated inside infected cells by viral thymidine kinase. The resulting triphosphate form competitively inhibits viral DNA polymerase, causing premature termination of viral DNA chains and thereby halting viral replication while sparing uninfected cells.

The dosage of Medovir is determined by the prescribing clinician based on the specific indication, patient age, weight, renal function, and severity of infection. Healthcare professionals adjust the infusion rate and total daily amount to achieve optimal therapeutic levels while minimizing toxicity.

Safety data for aciclovir in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Medovir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Medovir (intravenous aciclovir) offers rapid plasma concentrations suitable for severe or systemic herpesvirus infections, whereas oral agents like valacyclovir or famciclovir are used for milder cases. Compared with newer antivirals, aciclovir has a well‑established safety profile but may require dose adjustment in renal impairment.

Medovir should be stored at room temperature, below 25 °C, in its original packaging. Keep the solution protected from moisture and direct light. Do not freeze. Before administration, inspect the product for particulate matter and ensure aseptic handling according to standard IV preparation procedures.

Medovir is given by intravenous infusion. The recommended infusion rate and total daily dose are set by the treating physician, who may divide the total amount into multiple infusions per day. Administration should be performed by qualified healthcare personnel using sterile technique.

The most serious adverse events associated with intravenous aciclovir include acute renal failure, seizures, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of nephrotoxicity, neurological changes, and hypersensitivity throughout treatment.

Medovir is contraindicated in individuals with known hypersensitivity to aciclovir or any component of the formulation. Caution is advised for patients with severe renal impairment, as dose adjustment may be required, and for those with a history of severe allergic reactions to antiviral agents.